Is Buying Forty Seven Inc (NASDAQ:FTSV), Having Lower Short Interest a Winning Strategy?

The stock of Forty Seven Inc (NASDAQ:FTSV) registered a decrease of 4.8% in short interest. FTSV’s total short interest was 1.82M shares in August as published by FINRA. Its down 4.8% from 1.91 million shares, reported previously. With 226,200 shares average volume, it will take short sellers 8 days to cover their FTSV’s short positions. The short interest to Forty Seven Inc’s float is 13.52%.

The stock decreased 3.90% or $0.26 during the last trading session, reaching $6.4. About 511,098 shares traded or 59.13% up from the average. Forty Seven, Inc. (NASDAQ:FTSV) has declined 45.86% since August 15, 2018 and is downtrending. It has underperformed by 45.86% the S&P500.

Forty Seven Inc., a clinical-stage immuno-oncology company, focuses on developing therapies to activate macrophages for the treatment of cancer. The company has market cap of $270.18 million. It is developing 5F9, a humanized IgG4 subclass monoclonal antibody against CD47 that is in Phase 1b/2 clinical trials used for the treatment of cancer; and FSI-189, an antibody that binds to SIRPa for the treatment of solid tumors. It currently has negative earnings. The firm was formerly known as CD47 Sciences, Inc.

More notable recent Forty Seven, Inc. (NASDAQ:FTSV) news were published by: which released: “44 Stocks Moving In Wednesday’s Mid-Day Session – Benzinga” on July 17, 2019, also with their article: “Forty Seven down 10% after Q1 report – Seeking Alpha” published on May 14, 2019, published: “60 Biggest Movers From Yesterday – Benzinga” on July 18, 2019. More interesting news about Forty Seven, Inc. (NASDAQ:FTSV) were released by: and their article: “Forty Seven, Inc. (FTSV) Q2 Earnings Call Transcript – Yahoo Finance” published on August 14, 2019 as well as‘s news article titled: “Forty Seven Inc. to Present at Canaccord Genuity 39th Annual Growth Conference – GlobeNewswire” with publication date: July 31, 2019.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.